Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
2008 1
2011 1
2012 2
2018 1
2019 1
2021 1
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Results by year

Filters applied: . Clear all
The following terms were ignored: %, %, %, %, %
The following terms were not found in PubMed: 22Barrett, 2Fsurgery, 5BMeSH
Page 1
Impact of Pembrolizumab Versus Chemotherapy as Second-Line Therapy for Advanced Esophageal Cancer on Health-Related Quality of Life in KEYNOTE-181.
Adenis A, Kulkarni AS, Girotto GC, de la Fouchardiere C, Senellart H, van Laarhoven HWM, Mansoor W, Al-Rajabi R, Norquist J, Amonkar M, Suryawanshi S, Bhagia P, Metges JP. Adenis A, et al. J Clin Oncol. 2022 Feb 1;40(4):382-391. doi: 10.1200/JCO.21.00601. Epub 2021 Nov 3. J Clin Oncol. 2022. PMID: 34730989 Clinical Trial.
PATIENTS AND METHODS: HRQoL was measured using the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30), EORTC QLQ EC questionnaire (OES18), and EuroQol 5-dimension questionnaire (EQ-5D). Data were analyzed in p …
PATIENTS AND METHODS: HRQoL was measured using the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questi …
Triple induction chemotherapy and chemoradiotherapy for locally advanced esophageal cancer. A phase II study.
Eisterer W, DE Vries A, Kendler D, Spechtenhauser B, Königsrainer A, Nehoda H, Virgolini I, Lukas P, Bechter O, Wöll E, Ofner D. Eisterer W, et al. Anticancer Res. 2011 Dec;31(12):4407-12. Anticancer Res. 2011. PMID: 22199307 Clinical Trial.
BACKGROUND: This phase II trial assessed the feasibility and safety of induction chemotherapy with cisplatin (25 mg/m(2) d1-5, d29-34)/docetaxel (75 mg/m(2) d1, d29)/5-fluorouracil (5-FU, 750 mg/m(2) d1-5, d 29-34) followed by external beam radiotherapy concurrent with docetaxel …
BACKGROUND: This phase II trial assessed the feasibility and safety of induction chemotherapy with cisplatin (25 mg/m(2) d1-5, d29-34)/docet …
Radiofrequency ablation compared with argon plasma coagulation after endoscopic resection of high-grade dysplasia or stage T1 adenocarcinoma in Barrett's esophagus: a randomized pilot study (BRIDE).
Peerally MF, Bhandari P, Ragunath K, Barr H, Stokes C, Haidry R, Lovat L, Smart H, Harrison R, Smith K, Morris T, de Caestecker JS. Peerally MF, et al. Gastrointest Endosc. 2019 Apr;89(4):680-689. doi: 10.1016/j.gie.2018.07.031. Epub 2018 Aug 1. Gastrointest Endosc. 2019. PMID: 30076843 Clinical Trial.
BACKGROUND AND AIMS: Endoscopic resection (ER) is safe and effective for Barrett's esophagus (BE) containing high-grade dysplasia (HGD) or mucosal adenocarcinoma (T1A). ...Recruitment, retention, dysplasia clearance, clearance of benign BE, adverse events, healthcare costs …
BACKGROUND AND AIMS: Endoscopic resection (ER) is safe and effective for Barrett's esophagus (BE) containing high-grade dysplasia (HG …
A novel four-dimensional radiotherapy planning strategy from a tumor-tracking beam's eye view.
Li G, Cohen P, Xie H, Low D, Li D, Rimner A. Li G, et al. Phys Med Biol. 2012 Nov 21;57(22):7579-98. doi: 10.1088/0031-9155/57/22/7579. Epub 2012 Oct 26. Phys Med Biol. 2012. PMID: 23103415
For planning tumor volume (PTV) coverage, the difference between the DVH(3.5D) and iDVH(4D) was negligible (<1% area), whereas the DVH(3.5D) and DVH(4D) were quite different, due to DIR uncertainty (2 mm), which propagates to PTV dose coverage with a pronounced u …
For planning tumor volume (PTV) coverage, the difference between the DVH(3.5D) and iDVH(4D) was negligible (<1% area), whereas the …
Selective dose escalation of chemoradiotherapy for locally advanced esophageal cancer.
Seung SK, Smith JW 2nd, Ross HJ. Seung SK, et al. Dis Esophagus. 2008;21(7):589-95. doi: 10.1111/j.1442-2050.2008.00822.x. Epub 2008 Apr 22. Dis Esophagus. 2008. PMID: 18430177 Clinical Trial.
Patients received a continuous infusion of 5-fluorouracil 225 mg/m(2) on days 1 to 38 and intravenous paclitaxel 45 mg/m(2) and carboplatin AUC 2 on days 1, 8, 15, 22, 29, and 36. Radiotherapy was delivered in 1.8-Gy fractions, 5 d/wk for 5.5 weeks. ...Median follow-up was …
Patients received a continuous infusion of 5-fluorouracil 225 mg/m(2) on days 1 to 38 and intravenous paclitaxel 45 mg/m(2) and carboplatin …
[A multi-centered randomized controlled study of neo-adjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of esophagus: an interim analysis].
YANG H, FU JH, LIU MZ, FANG WT, WANG JM, CHEN YP, CHEN ZJ, XIANG JQ, YANG HJ, MAO WM, ZHENG X, ZHU CC, KONG M, HAN YT, LI T. YANG H, et al. Zhonghua Yi Xue Za Zhi. 2012 Apr 17;92(15):1028-32. Zhonghua Yi Xue Za Zhi. 2012. PMID: 22781642 Clinical Trial. Chinese.
METHODS: Patients with IIB, III staged squamous cell carcinoma of thoracic esophagus were randomly allocated to either preoperative chemoradiotherapy followed by surgery (arm A) or surgery alone (arm B). ...Cisplatin at 75 mg/m(2) was administered by an intravenous infusio …
METHODS: Patients with IIB, III staged squamous cell carcinoma of thoracic esophagus were randomly allocated to either preoperative c …
[Induction treatment of locally advanced operable cancers of the esophagus. Prognostic significance of the histologic response].
Thomas P, Doddoli C, Giacoia A, Garbe L, Perrier H, Giovannini M, Seitz JF, Hannoun-Levi JM, Giudicelli R, Fuentes P. Thomas P, et al. Ann Chir. 1997;51(3):222-31. Ann Chir. 1997. PMID: 9297883 French.
Chemoradiation included 2 cycles associating continuous 5 FU from D1 to 5 and from D22 to 26, cisplatyl on D1 and D22, 15 Gy/5d from D1 to 5 and from D22 to 26. Histopathological response was assessed on the operative specimens by routine examination of serial thin section …
Chemoradiation included 2 cycles associating continuous 5 FU from D1 to 5 and from D22 to 26, cisplatyl on D1 and D22, 15 Gy/5d from …